相关实验视频

Updated: Jun 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

打击氨基糖化物耐药性:从结构和功能特征到RKAAT的治疗挑战

Sarah Oluwatobi Otun¹, Richard Graca¹, Ikechukwu Achilonu¹

¹Department of Molecular and Cell Biology, Protein Structure-function Unit, University of Witwatersrand, Johannesburg, South Africa.

Current protein & peptide science

|February 5, 2024

概括

这项研究详细介绍了氨基糖化物修饰酶 (AME) 和它们在抗生素耐药性中的作用,重点关注复合克莱布西拉肺炎氨基糖化物基转移酶 (RKAAT). 它探讨了RKAAT的RKAAT.

科学领域:

微生物学和分子生物学
生物化学和酶学生物化学和酶学
传染病与公共卫生问题

背景情况:

抗生素耐药性的增加需要了解氨基糖体修饰酶 (AME).
由于耐药性,Klebsiella pneumoniae感染越来越令人担忧.
氨基糖化物是面临耐药性挑战的关键抗生素.

研究的目的:

探索AME的特征,功能和抵抗机制.
为了研究重组克莱布西拉肺炎氨基甘油酸基转移酶 (RKAAT),其特征和耐药性传递.
评估RKAAT介导耐药性的挑战,治疗和控制策略.

主要方法:

关于AME和氨基糖化物耐药性的综合文献综述.
详细检查RKAAT的生物物理特性和抵抗机制.
分析当前的治疗方式和感染控制策略.

主要成果:

描述AMEs在抗生素耐药性的结构和功能作用.
确定RKAAT作为Klebsiella pneumoniae对氨基糖化物耐药性的关键酶.
评估现有治疗干预措施的局限性和潜力.

结论:

了解像RKAAT这样的AMEs对于打击抗生素耐药性至关重要.
针对RKAAT介导的耐药性提供了潜在的治疗途径.
需要综合策略来解决和减轻细菌耐药性.

关键词:

(3) (9) 腺转移酶 (RKAAT).亚丁烯基转移酶是什么?克莱布西拉肺炎是一种肺炎.克莱布西拉肺炎 (Klebsiella pneumoniae) 是一种氨基糖化物.氨基糖化物抗生素氨基糖化物抗生素抗生素耐药性抗生素耐药性与医疗保健相关的感染再组合剂的使用情况.

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

相关概念视频

Antibiotic Selection

Antibiotic Selection

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...